Results 41 to 50 of about 5,666,574 (155)

Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation

Frontiers in Ophthalmology
We report a case of thyroid eye disease (TED) reactivation, review the literature, and raise awareness of severe ophthalmopathy and myositis following the initiation of cancer treatment with an immune checkpoint inhibitor (ICI).
Samantha Madala, Alomi Parikh, Alomi Parikh, Kendra Hong, Michael Burnstine, Michael Burnstine   +5 more
doaj   +1 more source

The epidemiological characteristics of patients with thyroid eye disease in a referral center in northern Iran

Journal of Current Ophthalmology, 2018
Purpose: This study was conducted to determine the demographics, clinical features, severity, and activity of thyroid eye disease (TED) in patients of a referral center in the north of Iran.
Abdolreza Medghalchi, Mitra Akbari, Yousef Alizadeh, Reza Soltani Moghadam   +3 more
doaj   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED

Journal of the Endocrine Society, 2023
Abstract Disclosure: K. Foster: Employee; Self; Viridian Therapeutics Inc. B.A. Dickinson: Employee; Self; Viridian Therapeutics Inc. R.M. Summerfelt: Employee; Self; Viridian Therapeutics Inc. A. She: Employee; Self; Viridian Therapeutics Inc. V. Bedian: Employee; Self; Viridian Therapeutics Inc. B.
Foster, Kelly, Dickinson, Brent A, Summerfelt, Rochelle M, She, Angela, Bedian, Vahe, Katz, Barrett   +5 more
openaire   +1 more source

Transcriptomic and Neuroimaging Decoding of Brain‐Immune Crosstalk in Thyroid Eye Disease

Advanced Science, Volume 13, Issue 27, 13 May 2026.
This study employed an imaging transcriptomics framework integrating resting‐state fMRI with Allen Human Brain Atlas transcriptomic data, coupled with peripheral blood RNA sequencing, to decode brain‐immune crosstalk in thyroid eye disease. Frontal, parietal, subcortical, and brainstem regions were identified as key neuroimmune‐ vulnerable regions ...
Haiyang Zhang, Yuting Liu, Shufan Jiang, Zilin Fang, Mengda Jiang, Xiaofeng Tao, Tianyi Zhu, Jipeng Li, Sijie Fang, Xuefei Song, Yinwei Li, Jing Sun, Chuanjun Tong, Zhengrun Gao, Huifang Zhou, Xianqun Fan   +15 more
wiley   +1 more source

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Advanced Science, Volume 13, Issue 18, 27 March 2026.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu, Huiyuan Ma, Tinghui Zhu, Shuwei Huang, Manxi Lu, Qiong Wang, Zai‐Long Chi   +6 more
wiley   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Orbital lymphocyte populations in three states of thyroid eye disease

American Journal of Ophthalmology Case Reports, 2023
Purpose: We report histopathologic orbital tissue analysis from three patients with thyroid eye disease (TED) – active, chronic, and post-teprotumumab to better characterize orbital cellular populations in these varying states of TED.
Shane M. Griffin, Rona Z. Silkiss
doaj   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

Thyroid Eye Disease

, 2022
Thyroid eye disease (TED), an autoimmune inflammatory disorder of the orbit, presents with a potential array of clinical sequelae. The pathophysiology behind TED has been partially characterized in the literature.
Alberto G. Distefano, Raquel Pinto, Emily Li, Ramy Rashad, Li, Emily, Distefano, Alberto G., Pinto, Raquel, Mahsa Sohrab, Rashad, Ramy, Sohrab, Mahsa   +9 more
core   +1 more source